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Background: The aim was to examine the association between smoking cessation and prognosis in smoking-related cancer as it is
unclear that cessation reduces mortality.
Methods: In this retrospective cohort study from 1999 to 2013, we assessed the association between cessation during the first year
after diagnosis and all-cause and cancer-specific mortality.
Results: Of 2882 lung, 757 upper aero-digestive tract (UAT) and 1733 bladder cancer patients 27%, 29% and 21% of lung, UAT and
bladder cancer patients quit smoking. In lung cancer patients that quit, all-cause mortality was significantly lower (HR: 0.82 (0.74–
0.92), while cancer-specific mortality (HR: 0.89 (0.76–1.04) and death due to index cancer (HR: 0.90 (0.77–1.05) were non-significantly
lower. In UAT cancer, all-cause mortality (HR: 0.81 (0.58–1.14), cancer-specific mortality (HR: 0.84 (0.48–1.45), and death due to
index cancer (HR: 0.75 (0.42–1.34) were non-significantly lower. There was no evidence of an association between quitting and
mortality in bladder cancer. The HRs were 1.02 (0.81–1.30) for all-cause, 1.23 (0.81–1.86) for cancer specific, and 1.25 (0.71–2.20) for
death due to index cancer. These showed a non-significantly lower risk in sensitivity analyses.
Conclusions: People with lung and possibly UAT cancer who quit smoking have a lower risk of mortality than people who continue
smoking.
Around a fifth of all cancers worldwide are caused by smoking
(Ezzati et al, 2005), and smoking-related tumours commonly
develop in the lung, upper aero-digestive tract (UAT) and bladder
(Thun et al, 2009) (US Surgeon General, 2014b). Although 5-year
survival rates for lung cancer are low, as most patients present in
late stages (Verdecchia et al, 2007; Walters et al, 2013), around 70%
of patients who are treated curatively survive for 5 years (UK. CR,
2016). The proportion of people with curatively treated cancer is
likely to increase with the advent of computerised tomography-
based lung cancer screening. In upper aerodigetsive tract (UAT)
and bladder cancer, the European mean age-standardised 5-year
survival rates are B40 and 70%, respectively (De Angelis et al,
2014). Thus, there is a large group of people with smoking-related
cancer who may benefit from additional interventions to improve
prognosis.
There is some evidence that quitting smoking after diagnosis of
smoking-related cancers may be associated with improved
prognosis, particularly in patients who have been diagnosed in
early stages (Aveyard et al, 2002; Parsons et al, 2010; US Surgeon
General, 2014b). However, many of these studies have methodo-
logical limitations such as a small sample size and unclear
definitions of smoking status (Gritz et al, 2014). In addition, most
studies compare the prognosis in patients who are smoking at
diagnosis to those who have quit some time before or who have
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never smoked. Few studies have focused on the prognostic benefit
of quitting at or soon after diagnosis (Land, 2012; Balough et al,
2014; US Surgeon General, 2014b).
Many patients with smoking-related cancers are still smoking at
diagnosis (Cooley et al, 2009; Park et al, 2012; Warren et al, 2013a)
and support to quit is not routinely offered as part of cancer care
(Murray et al, 2012; Warren et al, 2013b). If quitting soon after
diagnosis improved prognosis, this would increase the clinical
imperative to offer patients smoking cessation interventions to
improve their chances of survival. Unlike many treatments for
cancer, smoking cessation treatment is safe and has mild adverse
effects. In order to investigate if quitting after diagnosis has
prognostic benefits, we estimated the association between quitting
and all-cause mortality in lung, UAT and bladder cancer patients
using a large data set of the routinely-collected primary care data.
Cessation reduces mortality from cardiorespiratory disease and
thus cessation would be expected to reduce mortality from this
cause. We therefore investigated whether some of the benefit could
be due to prevention of cancer progression by examining the
association between quitting and death due to cancer.
MATERIALS AND METHODS
We conducted a retrospective cohort study using routinely-
collected UK primary care records from the Clinical Practice
Research Datalink (CPRD) (www.cprd.com). The protocol was
approved by the Independent Scientific Advisory Committee
(ISAC) for MHRA database research (reference no: 14_105), and
was made available during the peer review process. Patients with a
first diagnosis of lung, UAT and bladder cancers between 1999 and
2013 who smoked at diagnosis, survived for one year, had been
registered with a practice for at least one year and had at least one
year of follow-up data were included in the cohort. UAT cancers
mainly included cancers that occur in the mouth and throat, and
full definitions, and the Read codes used for each cancer are
provided in Appendix 1 (HSCIC, 2014). We restricted the analysis
to patients that survived for at least 1 year to limit confounding by
stage of cancer at diagnosis. Stage was not recorded in most cases.
People with advanced cancer-treated palliatively may be less likely
to stop smoking and are more likely to die, thus confounding the
association between smoking cessation and mortality. As many
such patients die within a year, restricting the analysis in this way
limited confounding. Patients were followed-up until the end of
2013 or death, or were censored if they moved practice. In 2013,
the CPRD database contained records from 4.4 million live patients
in 674 practices, which represented 6.9% of the UK population
(Herrett et al, 2015). The first version of the protocol was amended
to exclude people with thyroid cancer because this is not a
smoking-related head and neck cancer.
Patients were defined as smokers at diagnosis if they were
recorded as smoking on the last occasion smoking status was
updated within the 3 years prior to diagnosis. People were
classified as having stopped smoking or continued smoking during
the first year of follow-up if their last record during that period
recorded either state. Some people did not have their smoking
status updated after diagnosis, and we conducted sensitivity
analyses to examine the impact of this on the findings.
Survival time was calculated as the time from the end of the first
year after diagnosis until outcome occurrence (all-cause mortality,
cancer-specific mortality or death due to index cancer). The fact of
death was taken from the CPRD record and also from the UK
national system of recording death provided by the Office for
National Statistics (ONS) and this was used for all-cause mortality
analyses. The CPRD database does not record cause of death but
ONS does. Thus, for those patients in practices where the ONS
death data could be linked, we examined cancer-specific mortality
and death due to index cancer. To do so, the ONS data were linked
to each person’s CPRD data. In the protocol, we planned to
investigate development of a recurrence or development of a
second primary tumour but were unable to do this as these
outcomes were poorly recorded.
Survival curves were generated with the Kaplan–Meier plot
method for each outcome. We used Cox proportional hazard
regression models to compare differences in survival between
people who stopped and people who continued smoking in each
cancer group. The proportional hazards assumption was examined
by the use of log–log plots and Schoenfeld residuals. The results are
presented as hazard ratios with 95% confidence intervals, and we
use the term non-significant as shorthand to mean that the 95%
confidence intervals included unity. In the main analyses, we
adjusted for age, gender, socio-economic status (SES), comorbidity
(asthma, chronic kidney disease (CKD), chronic obstructive
pulmonary disease (COPD), diabetes, hypertension, peripheral
arterial disease (PAD), stroke, psychoses), treatment and alcohol
consumption. Patients whose smoking status after diagnosis was
missing, were included as an additional exposure category. Due to
missing data on smoking status after diagnosis, alcohol status and
SES we used multiple imputation (MI) models to impute these
data. We used the mi command in STATA 14 with 20 imputed
datasets, including the baseline and clinical characteristics, out-
come and the Nelson–Aalen estimator of the cumulative hazard
function (White and Royston, 2009).
Sensitivity analyses were conducted to investigate the robustness
of MI models. Sensitivity analyses comprised unadjusted analysis,
full case analysis and full case analysis, where patients that did not
have their smoking status updated within the year following
diagnosis were classified as continued smokers. We performed two
additional sensitivity analyses but do not show the data as the
results of these analyses were very similar to the main results. First,
we excluded covariates with missing data (alcohol status and SES).
Second, in response to a referee, we adjusted for year of diagnosis,
which made no material difference, and then added a multi-
plicative interaction term between smoking status and year of
diagnosis, and this was not significant in any analysis.
RESULTS
During the study period, there were a total of 42 112 incident
cancer cases (lung n¼ 27 615, UAT n¼ 3248, bladder n¼ 11 249).
Information regarding smoking status at diagnosis was available
for 81% of these cases (lung 83%, UAT 78%, bladder 79%), and we
assumed that patients with missing status were either never
smokers, or long-term ex-smokers, consistent with the rules GPs
for updating smoking status (Marston et al, 2014). On the basis of
this assumption, 36%, 35% and 20% of lung, UAT and bladder
cancer patients were smoking at diagnosis. We included in our
analyses patients who smoked at diagnosis and who had survived
for at least 1 year. This included 2882 people with lung cancer
(27% quit, 39% continued, 34% unknown), 757 people with UAT
cancer (29% quit, 37% continued, 34% unknown) and 1733 people
with bladder cancer (21% quit, 49% continued, 30% unknown). As
not every practice in the CPRD database is linked to ONS for the
cause of death analyses, the cohorts for the analyses of cancer-
specific mortality and death due to index cancer were smaller (lung
cancer n¼ 1635; UAT cancer n¼ 428; bladder cancer n¼ 1013)
(Figure 1).
The baseline demographic characteristics were similar across
smoking exposure groups (quit during first year, continued during
first year, no smoking update during first year) for each cancer
group. There were some imbalances in the presence of
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comorbidities across exposure groups for each cancer group
(Table 1). A higher proportion of patients who quit smoking
received surgery. However, these baseline characteristics were
controlled for in the analyses.
Association between smoking status after diagnosis and all-
cause mortality. Lung cancer patients who quit smoking had a
significantly lower risk of all-cause mortality compared with
patients who continued to smoke (unadjusted HR: 0.71 (95% CI:
0.63–0.79), adjusted HR: 0.82 (95% CI: 0.74–0.92)) (Table 2).
Median survival (from 1 year after diagnosis) for patients who
continued smoking was 1.08 years (95%CI: 0.94–1.24), and was
1.97 years (1.68–2.26) for patients who quit. In UAT, quitting
smoking was associated with a non-significantly lower risk of
mortality, which was unchanged after adjustment (unadjusted HR:
0.80 (0.60–1.08), adjusted HRL 0.81 (0.58–1.14)). There was no
evidence of an association between quitting and mortality in
patients with bladder cancer (unadjusted HR: 0.91 (95% CI:
0.73–1.14), adjusted HR: 1.02 (0.81–1.30)) (Figure 2). The
sensitivity analysis with different assumptions produced very
similar results to these for all cancers (Table 2).
Association between smoking status after diagnosis and cancer-
specific mortality. Of all the people diagnosed with lung cancer,
86% died of lung cancer. Quitting smoking after a diagnosis of lung
cancer was associated with lower cancer-specific mortality
(unadjusted HR: 0.73 (0.62–0.85)), but this became non-significant
after adjustment (HR: 0.89 (0.76–1.04)) (Table 2). Less than two
thirds of the deaths after UAT and bladder cancer were due to
cancer (65 and 59%, respectively). Quitting smoking after diagnosis
Lung cancer
n = 27615 
Bladder cancer
n = 11249 
Upper aero-digestive
tract cancer
n = 3248  
Current smokers at diagnosis with at least one year of follow up
(included in all-cause mortality analyses)
            n = 2882
 
Continued = 1129 (39%)
Quit           = 784   (27%)
Unknown   = 969   (34%)
              n = 757
 
Continued = 281 (37%)
Quit           = 216 (29%)
Unknown   = 260 (34%)   
n = 1733 
Continued = 850 (49%) 
Quit          = 356 (21%)
Unknown  = 527 (30%)
Patients with linkage to ONS mortality data (included in cancer specific mortality and death due to
index cancer analyses) 
              n =1635
Continued = 625 (38%)
Quit           = 466 (29%)
Unknown  = 544 (33%)  
               n = 428
Continued = 154 (40%)
Quit           = 120 (20%)
Unknown   = 154 (20%)  
              n = 1013
Continued = 494 (49%)
Quit           = 207 (20%) 
Unknown   = 312 (31%)   
Figure 1. Flow of participants through the study.
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of either cancer was not significantly associated with reduced
cancer-specific mortality (Table 2, Figure 3). Sensitivity analysis
again showed very similar results.
Association between smoking status after diagnosis and death
due to index cancer. There was no significant association between
quitting smoking and death due to index cancer in lung
(unadjusted HR: 0.72 (0.61–0.85), adjusted HR: 0.90 (0.77–1.05,
UAT (unadjusted HR: 0.78 (0.45–1.37), adjusted HR: 0.75 (0.42–
1.34) or bladder cancer patients (unadjusted HR: 1.24 (0.77–1.99),
adjusted HR: 1.25 (0.71–2.20)) (Table 2, Figure 4). Sensitivity
analysis produced similar results for lung and UAT cancers but
there was a modest difference between the multiple imputation and
the full case models for bladder cancer. However, neither set of
models suggested a significant increase or decrease in risk for
people who stopped smoking.
DISCUSSION
A third of patients with lung and UAT cancer, and a fifth of those
with bladder cancer smoked at diagnosis, and the majority
continued after their diagnosis. In patients who survived for at
least 1 year, smoking cessation during that first year was associated
with a lower risk of all-cause mortality in lung cancer and the
evidence was suggestive of a lower risk in UAT cancer. There was
inconclusive evidence that quitting was associated with survival in
bladder cancer. There was inconclusive evidence that smoking
cessation was associated with lower mortality in each cancer type.
This study included many more people than previous studies
investigating the impact of smoking cessation on survival, therefore
producing more precise estimates of association. However, there
were fewer people with data available on cause of death. This
meant that the estimates for cancer-specific outcomes were less
precise and it was not possible to be sure whether the apparent
survival benefit arose from reduced deaths from cardiac and
respiratory causes or from reduced deaths due to cancer in UAT
cancer because the confidence intervals for cancer-specific deaths
were wider. However, for lung cancer, it appears clearer that
quitting smoking is associated with a lower cancer-specific
mortality, mainly because the large majority of deaths were due
to lung cancer, although the adjusted estimates of cancer-specific
mortality (based on a subsample) were not themselves significant.
This study has some limitations. Firstly, smoking status was
taken from the medical records and these may not accurately
record true smoking status. Doctors did not record whether around
a third of people continued or stopped smoking, though sensitivity
analysis suggest the results were insensitive to this. Some people
Table 1. Baseline characteristics of patients with lung, bladder and upper aero-digestive tract cancer by smoking exposure status
Lung cancer Upper aero-digestive tract cancer Bladder cancer
Characteristics
Continued
smoking
(N¼1129,
39%)
Quit
smoking
(N¼784,
27%)
Status not
updated
(N¼969,
34%)
Continued
smoking
(N¼281,
37%)
Quit
smoking
(N¼216,
29%)
Status not
updated
(N¼260,
34%)
Continued
smoking
(N¼850,
49%)
Quit
smoking
(N¼356,
21%)
Status not
updated
(N¼527,
30%)
Gender (% male) 588 (52.1%) 364 (46.4%) 484 (49.9%) 197 (70.1%) 143 (66.2%) 181 (69.6%) 618 (72.7%) 269 (75.6%) 418 (79.3%)
Age (mean, s.d. years) 67.1 (9.97) 66.3 (9.04) 65.8 (10.4) 59.65 (10.86) 61 (10.83) 59.96 (11.2) 67.49 (10.7) 65.39 (10.8) 66.14 (11.5)
Patients with ONS
linkage
625 (55.4%) 466 (59.4%) 544 (56.1%) 154 (54.8%) 120 (55.6%) 154 (59.2%) 494 (58.1%) 207 (58.15%) 312 (59.2%)
Alcohol status
Non drinkers 264 (23.4%) 180 (22.9%) 216 (22.3%) 36 (12.8%) 35 (16.2%) 38 (14.6%) 228 (26.8%) 96 (27%) 126 (23.9%)
Ex-drinkers 103 (9.1%) 54 (6.9%) 49 (5%) 22 (7.8%) 13 (6%) 9 (3.5%) 85 (10%) 22 (6.2%) 20 (3.8%)
Light drinkers 101 (9%) 55 (7%) 75 (7.7%) 18 (6.4%) 25 (11.6%) 24 (9.2%) 65 (7.7%) 35 (9.8%) 55 (10.4%)
Moderate drinkers 100 (8.9%) 63 (8%) 65 (6.7%) 39 (13.9%) 29 (13.4%) 37 (14.2%) 79 (9.3%) 29 (8.2%) 38 (7.2%)
Heavy drinkers 30 (2.7%) 10 (1.3%) 20 (2.1%) 26 (9.3%) 11 (5.1%) 16 (6.2%) 16 (1.9%) 4 (1.1%) 8 (1.5%)
Drinkers (unknown
amount)
60 (5.3%) 30 (3.8%) 25 (2.6%) 18 (6.4%) 8 (3.7%) 13 (5%) 28 (3.3%) 25 (7%) 8 (1.5%)
No record found 471 (41.7%) 392 (50%) 519 (53.6%) 122 (43.4%) 95 (43.8%) 123 (47.3%) 349 (41.1%) 145 (40.7%) 272 (51.6%)
IMD scorea
1 63 (5.6%) 68 (8.7%) 90 (9.3%) 9 (3.2%) 15 (6.9%) 19 (7.3%) 64 (7.5%) 36 (10.1%) 55 (10.4%)
2 105 (9.3%) 88 (11.2%) 104 (10.7%) 26 (9.3%) 20 (9.3%) 29 (11.2%) 98 (11.5%) 54 (15.2%) 72 (13.7%)
3 121 (10.7%) 76 (9.7%) 116 (12%) 31 (11%) 30 (13.9%) 29 (11.2%) 100 (11.8%) 45 (12.6%) 61 (11.6%)
4 149 (13.2%) 110 (14%) 124 (12.8%) 47 (16.7%) 26 (12%) 38 (14.6%) 120 (14.1%) 47 (13.2%) 77 (14.6%)
5 179 (15.9%) 124 (15.8%) 102 (10.5%) 41 (14.6%) 26 (12%) 34 (13.1%) 105 (12.4%) 23 (6.5%) 45 (8.5%)
Missing 512 (45.4%) 318 (40.6%) 433 (44.7%) 127 (45.2%) 99 (45.8%) 111 (42.7%) 363 (42.7%) 151 (42.4%) 217 (41.2%)
Comorbidities
Asthma 127 (11.2%) 74 (9.4%) 56 (5.8%) 21 (7.5%) 11 (5.1%) 5 (1.9%) 67 (7.9%) 33 (9.3%) 15 (2.8%)
CKD 103 (9.1%) 62 (7.9%) 41 (4.2%) 12 (4.3%) 8 (3.7%) 9 (3.5%) 85 (10%) 24 (6.7%) 23 (4.4%)
COPD 370 (32.8%) 196 (25%) 143 (14.7%) 41 (14.6%) 27 (12.5%) 20 (7.6%) 140 (16.5%) 52 (14.6%) 25 (4.7%)
Diabetes 96 (8.5%) 85 (10.9%) 30 (3.1%) 20 (7.1%) 14 (6.5%) 5 (1.9%) 115 (13.5%) 34 (9.5%) 14 (2.7%)
Hypertension 263 (23.3%) 171 (21.8%) 130 (13.4%) 42 (14.9%) 61 (28.2%) 27 (10.4%) 223 (26.2%) 75 (21.1%) 78 (14.8%)
Peripheral arterial
disease
103 (9.1%) 50 (6.4%) 40 (4.1%) 14 (5%) 10 (4.6%) 8 (3.1%) 62 (7.3%) 15 (4.2%) 19 (3.6%)
Stroke 102 (9%) 49 (6.2%) 41 (4.2%) 6 (2.1%) 10 (4.6%) 5 (1.9%) 57 (6.7%) 17 (4.8%) 19 (3.6%)
Psychosis 12 (1.1%) 6 (0.8%) 7 (0.7%) 2 (0.7%) 2 (0.9%) 1 (0.4%) 10 (1.2%) 2 (0.6%) 4 (0.8%)
Treatment
Surgery 177 (15.7%) 264 (33.7%) 134 (13.8%) 60 (21.4%) 59 (27.3%) 68 (26.2%) 60 (7.1%) 44 (12.4%) 45 (8.5%)
Chemotherapy 338 (29.9%) 221 (28.2%) 309 (31.9%) 47 (16.7%) 33 (15.3%) 49 (18.8%) 113 (13.3%) 63 (17.7%) 76 (14.4%)
Radiotherapy 199 (17.6%) 98 (12.5%) 173 (17.9%) 75 (26.7%) 46 (21.3%) 63 (24.2%) 33 (3.9%) 7 (2.0%) 22 (4.2%)
Abbreviations: CKD=chronic kidney disease; COPD=chronic obstructive pulmonary disease; ONS=Office for National Statistics.
aIMD stands for index of multiple deprivation and is an area-based measure of socio-economic status which has been divided into quintiles, where 1 corresponds to least deprived and 5 to the
most deprived.
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who were recorded as having stopped smoking may have
subsequently relapsed, while some recorded as continuing may
subsequently stopped. This mixing of exposure assignment is likely
to underestimate the strength of association (Sorahan and
Gilthorpe, 1994; Wacholder et al, 1995), but it creates uncertainty.
Although we controlled for a range of confounders, we were unable
to adjust for all possible confounders. In particular, the data on
stage at diagnosis is not recorded in UK primary care notes so this
could not be controlled for in the analysis. There is no biologically
plausible reason why those who quit smoking after diagnosis would
present with more favourable stage than those who continued to
smoke. However, it is plausible that presenting with more
advanced cancer undermines motivation to stop smoking and that
this would confound the association, producing the associations in
the direction we observed. In addition, primary care records have
limited information on the treatment received and often this was
not recorded. Consequently, it was not possible to reliably
differentiate those treated curatively from those treated palliatively.
We confined the analysis to people who survived at least a year to
try to limit this confounding, but this may not have been entirely
successful. In addition, SES and alcohol consumption were not well
recorded, and more than 20% of people had missing data for these
variables so we used multiple imputation models. These models
produced broadly similar results to the models that did not control
for these variables.
Interpretation and context with previous literature. Our find-
ings relating to all-cause mortality are consistent with other
published literature (Browman et al, 1993; Aveyard et al, 2002;
Clark et al, 2006; Mayne et al, 2009; Parsons et al, 2010) We have
previously reported a systematic review of studies in lung cancer
patients that found that, after adjustment for key prognostic
factors, quitting was associated with reduced mortality, with a HR
of 0.34 (95%CI: 0.13–0.87) for non-small cell cancer and 0.54
(95%CI: 0.39–0.75) for small cell lung cancer (Parsons et al, 2010).
Both these estimates were derived from only one study each, with
around 200 participants. Our study produced more modest
estimates of the benefits of quitting in lung cancer, but the point
estimates are within these confidence intervals. Similarly, studies
comparing mortality between people who quit smoking after
diagnosis of head and neck cancer and people who continue to
smoke have found lower mortality risk in those who quit. For
example, Mayne et al, 2009 reported a significantly lower risk of
mortality (HR: 0.30 95%CI: 0.16–0.57) (Mayne et al, 2009) and
Browman et al, 1993 reported improved two-year survival (66% vs
39%, P¼ 0.005). Studies in patients with bladder cancer have
compared rates of all-cause mortality in people who smoke at
diagnosis to those who have never smoked, or to those who have
quit some time before diagnosis, but not to people who quit after
diagnosis and therefore there is no evidence from previous studies
to compare our results with (Aveyard et al, 2002; Van Osch et al,
2016). In our analysis, we adjusted for common comorbidities, and
smoking cessation was still associated with a risk of death due from
any cause in lung cancer. There is strong evidence elsewhere that
quitting smoking reduces the risk of heart disease and respiratory
death (Critchley and Capewell, 2003), including from a clinical trial
(Anthonisen et al, 2002), and therefore we conclude that the
association between quitting and reduced all-cause mortality in
lung cancer is causal.
There is evidence that continued smoking increases risk of a
second primary cancer and recurrence (US Surgeon General,
2014a), but the evidence that quitting at the time of diagnosis
reduces this risk is relatively weak. For example, in our review of
lung cancer patients, both non-small cell and small cell lung cancer
patients who quit smoking had a lower risk of recurrence (NSCLC
HR: 0.54 (0.29–0.99); SCLC HR: 0.79 (0.67–0.94) and small cell
lung cancer patients had a lower risk of second primary tumour
although confidence intervals were wide (HR 0.23 (0.05–0.92)
(Parsons et al, 2010). Each of these estimates originate from one
study only which include a small numbers of patients (Kawahara
et al, 1998; Videtic et al, 2003; Nia et al, 2005). Do et al found that
in patients with early stage head and neck squamous cell
carcinoma, continued smokers and quitters were both more likely
to develop second primary tumours than never smokers. However,
when indirectly comparing continuing smokers and quitters
(Bucher et al, 1997)/ there was no evidence of a difference in
Table 2. Risk of all-cause mortality, cancer-specific mortality and death due to index cancer in quitters compared with continuing
smokers with lung, bladder and upper aero-digestive tract cancer
Ppts
(n)
Total
deaths
(n)
All-cause
mortality
HR (95% CI)
Ppts
(n)
Total
deaths
(n)
Cancer-
specific
mortality
HR (95% CI)
Ppts
(n)
Total
deaths
(n)
Death due
to index
cancer
HR (95% CI)
Lung cancer
Unadjusted–missing exposure (extra category) 2881 2016 0.71 (0.63–0.79) 1635 1025 0.73 (0.62–0.85) 1635 954 0.72 (0.61–0.85)
Primary model (MI model–alcohol, SES, exposure)a 2881 2016 0.82 (0.74–0.92) 1635 1025 0.89 (0.76–1.04) 1635 954 0.90 (0.77–1.05)
Full case analysis with missing exposure as
categorya
835 617 0.82 (0.66–1.00) 835 529 0.87 (0.70–1.10) 835 496 0.87 (0.69–1.10)
Full case analysis (classify missing exposure as
continued smokers)a
835 617 0.83 (0.69–1.00) 835 529 0.87 (0.70–1.10) 835 496 0.84 (0.68–1.04)
Upper aero-digestive tract cancer
Unadjusted–missing exposure (extra category) 757 313 0.80 (0.60–1.08) 428 120 0.96 (0.61–1.51) 428 81 0.78 (0.45–1.37)
Primary model (MI model–alcohol, SES, exposure)a 757 313 0.81 (0.58–1.14) 428 120 0.84 (0.48–1.45) 428 81 0.75 (0.42–1.34)
Full case analysis with missing exposure as
categorya
233 106 0.72 (0.40–1.27) 233 71 0.88 (0.46–1.68) 233 49 0.71 (0.31–1.62)
Full case analysis (classify missing exposure as
continued smokers)a
233 106 0.71 (0.41–1.20) 233 71 0.90 (0.43–1.63) 233 49 0.66 (0.31–1.42)
Bladder cancer
Unadjusted–missing exposure (extra category) 1733 571 0.91 (0.73–1.14) 1013 213 1.23 (0.86–1.74) 1013 122 1.24 (0.77–1.99)
Primary model (MI model–alcohol, SES, exposure)a 1733 571 1.02 (0.81–1.30) 1013 213 1.23 (0.81–1.86) 1013 122 1.25 (0.71–2.20)
Full case analysis with missing exposure as
categorya
559 208 1.04 (0.72–1.52) 559 128 1.14 (0.71–1.83) 559 77 0.86 (0.44–1.65)
Full case analysis (classify missing exposure as
continued smokers)a
559 208 1.00 (0.70–1.43) 559 128 1.02 (0.66–1.58) 559 77 0.76 (0.41–1.41)
Abbreviations: ppts¼participants; (n)¼ number; MI¼multiple imputation.
aAdjusted for age, gender, SES, co-morbidity, treatment, alcohol consumption.
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risk (HR 0.94 (95%CI 0.34–2.60). Leon et al conducted a matched
case control study in patients with head and neck cancer and found
that quitters had a significantly lower risk of a second primary
neoplasm compared with those who continued to smoke (HR 0.34
(95%CI 0.24–0.56)) (Leon et al, 2009). In patients with superficial
transitional cell carcinoma of the bladder, Fleshner et al reported
data that allowed us to compare the risk of recurrence in patients
who quit smoking after diagnosis to those who continued to smoke
(Fleshner et al, 1999). Indirect comparison showed quitters were at
lower risk of recurrence, but it was not significant (HR 0.71 (0.48–
1.05)) (Aveyard et al, 2002). Taken together with our findings, the
evidence appears inconclusive that quitting smoking lowers the
risk of cancer progression in people with bladder cancer. However,
overall there is stronger evidence that quitting improves cancer
outcomes in UAT and lung cancer.
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Figure 2. Unadjusted risk of all-cause mortality in patients who quit
smoking compared with those who continued to smoke after
diagnosis. (A) Lung cancer; (B) Upper aero-digestive tract cancer;
(C) Bladder cancer.
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Figure 3. Unadjusted risk of cancer-specific mortality in patients who
quit smoking compared with those who continued to smoke after
diagnosis. (A) Lung cancer; (B) Upper aero-digestive tract cancer;
(C) Bladder cancer.
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There are several potential mechanisms by which continued
smoking may affect cancer-specific survival. Previous studies have
shown that continued smoking may reduce the effectiveness of
adjuvant cancer treatment (Dresler, 2003; Gritz et al, 2005; Zevallos
et al, 2009; Chen et al, 2011; Gajdos et al, 2012). For example,
tobacco smoke reduces plasma concentrations of chemotherapeutic
agents as it is a potent inducer of the cytochrome P450 enzymes
which metabolise several drugs in the liver, including some
chemotherapies (Dresler, 2003; Petros et al, 2012). In addition to
affecting treatment, constituents of tobacco smoke may also alter
the behaviour of cancer cells or aid processes that support tumour
development and progression (Yoshino and Maehara, 2007;
Warren et al, 2014). Cigarette smoke contains many potential
irritants and is a strong inflammatory stimulus (Lee et al, 2012;
Warren et al, 2014), and evidence is been mounting that an
inflammatory microenvironment aids development and progres-
sion of tumours (Balkwill and Mantovani, 2001; Aggarwal et al,
2006; Mantovani et al, 2008; Lee et al, 2012). It is possible that
these mechanisms may be at play in the increased risk of death
associated with continued smoking in lung and UAT cancers.
These results reinforce the need to provide active and ongoing
smoking cessation support for people with cancer who smoke
which is both a non-toxic and cost-saving intervention for the
patient. In addition to reduced survival, previous studies have
shown that continued smoking is associated with lower quality of
life (Garces et al, 2014) increased pain (Daniel et al, 2009),
treatment-related toxicity (Gritz et al, 2014; US Surgeon General,
2014b) and longer length of hospital stay in cancer patients
(Erhunmwunsee and Onaitis, 2009). Many patients try to quit on
diagnosis (Gritz et al, 1991), so those who relapse find themselves
involuntarily trapped by their addiction. The lesson of the Lung
Health Study, a study of people who continued smoking despite
COPD, is that continued support for smoking cessation, despite
early failure to quit, improves outcomes for patients (Scanlon et al,
2000). There is strong evidence that smoking cessation support in
hospitalised patients that continues for at least a month after
discharge increases rates of cessation (Rigotti et al, 2012). English
(NICE) guidance recommends that patients accessing secondary
care should be offered support to quit smoking within this setting,
and for inpatients, this should include referral to intensive
smoking cessation support which continues after discharge
(Excellence. NICE, 2013). Despite this, support for smoking
cessation is not well integrated into cancer care (Murray et al,
2012; Warren et al, 2013b) and future work should examine
interventions to improve the health system to provide treatment
for tobacco dependence.
CONCLUSION
Most lung, UAT and bladder cancer patients who smoke at
diagnosis continue smoking. However, quitting smoking reduces
the risk of death in lung cancer and may do so in UAT cancer, but
there is no evidence in this study that it does so in bladder cancer.
The reduction in risk of death may be due to a decreased risk of
cancer progression, but this needs further investigation.
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